David Esposito joins Armune BioScience

Kathy Jennings | Thursday, June 12, 2014

David Esposito

The medical diagnostics company Armune BioScience, Inc., is moving to commercialize technology exclusively licensed from the University of Michigan for diagnostic and prognostic tests for prostate, lung and breast cancers.

Specifically, the company is developing a strategy for Apifiny, a test for prostate cancer. It has hired David Esposito as its Chief Operating, a new position for the company.

He previously served President and General Manager of Phadia U.S. Inc, a specialty diagnostics company. Armune BioScience says Esposito helped drive significant growth in the U.S. market and played a vital leadership role in the sale of Phadia to ThermoFisher Scientific for $3.5 billion in 2011.

Esposito graduated from the United States Military Academy at West Point with a Bachelor of Science degree in Civil Engineering. He is a combat veteran, having served as an infantry platoon leader with the 101st Airborne Division and was awarded the Bronze Star Medal during the Persian Gulf War. David also earned a Master of Business Administration from Syracuse University.

“The proprietary technologies of Armune BioScience have significant potential to meet areas of crucial need in prostate, lung and breast cancer diagnostic and prognostic testing." Esposito says. "I look forward to helping the team prepare and execute on the commercial opportunities.”

Armune BioScience, Inc., was founded by the Apjohn Group, LLC, a business accelerator built by experienced health-care executives that brings together valuable resources of management talent and angel/seed financing, and a group of experienced life science professionals. Armune was incorporated as a Delaware Corporation, has its corporate headquarters in Kalamazoo, and a research and commercial laboratory facility in Ann Arbor.

Sources: Eli Thomssen, Armune BioScience, Inc. and Rick Chambers, Rick Chambers & Associates